Clinical trial
Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on…
NCT00432822 · Orphanetics Pharma Entwicklungs GmbH, Industry · Terminated
Key facts
| NCT number | NCT00432822 |
|---|---|
| Title | Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety |
| Official title | Double-Blind, Placebo Controlled, Multicentre Study With an Open Label Extension to Evaluate the Efficacy and Safety of Tetrahydrobiopterin (BH4) in Children and Adolescents With Hyperphenylalaninemia Caused by Phenylalanine Hydroxylase Deficiency |
| Lead sponsor | Orphanetics Pharma Entwicklungs GmbH, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Phenylalanine Hydroxylase Deficiencies |
| Intervention type | Drug |
| Interventions | tetrahydrobiopterin (BH4) |
| Enrollment | 50 |
| First posted | Feb 8, 2007 |
| Last update posted | Sep 20, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: